Johnson & Johnson (JNJ) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Johnson & Johnson · Health Care · ref. ETF XLV · 77 calls · price $265.77
What the company does: Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
📈 Johnson & Johnson (JNJ) stock price
$265.77+51.5% over range
Aug 28, 25low $174.16 · high $273.41Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
69% recommend buying · 13 analysts
📊 JPI status : Johnson & Johnson has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 JNJ price target & analyst consensus — price $266
The price target · all analysts combined (13 targets)
Highest target · 1 firm of 13$300+12.9%
Median target · of 13 targets$280+5.4%
Lowest target · 2 firms of 13$250-5.9%
Current price$265.77
Where these 13 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
754%
$280 ↔ $300
Below
646%
$250 ↔ $265
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $294 (+11 %), call made on July 17, 2026, maturing on July 17, 2027 (42 d ago).
The 7 reliable analysts
$287+8.0 %
The 6 other firms
$260-2.2 %
How to read it: the 7 reliable firms are not filtered by optimism — 5 aim above the price, 2 below, hence their $287 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 13 ratings (last 6 months)
Strong Buy00%
Buy969%
Hold431%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 JNJ price target all
All 13 calls, one by one, with our verdict on each firm.
→ See all 13 targets, analyst by analyst💡 The best analysts on JNJ most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in JNJ? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Johnson & Johnson? The JPI assistant answers using our backtest data.
💰 Johnson & Johnson dividend: yield, history & growth › open the full page
2.06%annual yield
📈 Steady dividend — 23 yrs of consecutive dividend increases
That's ~$5.24 per share per year.
📈 Johnson & Johnson fundamentals: valuation, margins & growth › open the full page
P/E 30.9Net margin 21.5 %Revenue growth +6.6 %High P/E
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 19 %
2023
Rev −10%Profit +96%
2024
Rev +4%Profit −60%
2025
Rev +6%Profit +91%
🔎 Detailed analyses
🏛️ Which US Congress members hold Johnson & Johnson (JNJ)?
15 Congress members have disclosed JNJ buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Kevin Hern 13× · 48%Lloyd Doggett 7× · 21%Kathy Manning 6× · 43%Blake Moore 5× · 39%K. Conaway 3× · 30%Cindy Axne 3× · 57%Richard Allen 3× · 42%Josh Gottheimer 2× · 56%John Curtis 2× · 62%Carol Miller 2× · 25%
✅ Historical analyst reliability on JNJ
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Deutsche Bank ↗ | 100% | +21.9% | 4 |
| Barclays ↗ | 100% | +11.4% | 5 |
| Morgan Stanley ↗ | 100% | +11.1% | 5 |
| Wells Fargo ↗ | 89% | +7.2% | 9 |
| UBS ↗ | 86% | +29.0% | 7 |
| RBC Capital ↗ | 83% | +18.9% | 23 |
| Jefferies ↗ | 80% | +20.5% | 5 |
| Cantor Fitzgerald ↗ | 80% | +3.6% | 40 |
| Argus Research ↗ | 75% | +12.6% | 4 |
| Credit Suisse | 69% | +4.0% | 16 |
See the other 5 firms
| SVB Leerink | 50% | +2.7% | 4 |
| BMO Capital ↗ | 50% | +4.2% | 2 |
| Citigroup ↗ | 59% | +11.9% | 17 |
| Raymond James ↗ | 65% | +7.5% | 23 |
| Goldman Sachs ↗ | 67% | +19.5% | 3 |
📊 What $1,000 invested in Johnson & Johnson would be worth › open the full page
In short — $1,000 invested in Johnson & Johnson 10 years ago would be worth $2,472 today, i.e. +9%/yr on average. Best year: 2025 (+43%), worst: 2023 (-11%). Price performance, excluding dividends.
If I'd invested $1,000 in Johnson & Johnson
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,756 | +76% |
| 3 years ago | $1,438 | +44% |
| 5 years ago | $1,614 | +61% |
Return by year (Johnson & Johnson)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +23% | $1,227 (+23%) |
| 2025 | +43% | $1,756 (+76%) |
| 2024 | -8% | $1,620 (+62%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Johnson & Johnson
Loading news…
📋 All analyst calls on JNJ
Filtered on — · ✕ show all
Guggenheim ↗
Aug 6, 26
▲ Buy · 🎯$287
Price at call : $256.98 — upside +12%
Today : $265.77 — upside +8%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Aug 6, 27
matures : Aug 6, 27
Wells Fargo ↗
Aug 3, 26
▲ Overweight · 🎯$282
Price at call : $254.93 — upside +11%
Today : $265.77 — upside +6%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
Guggenheim ↗
Jul 17, 26
▲ Buy · 🎯$270
Price at call : $253.04 — upside +7%
Today : $265.77 — upside +2%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 17, 27
matures : Jul 17, 27
Raymond James ↗
Jul 16, 26
▲ Outperform · 🎯$265
Price at call : $253.04 — upside +5%
Today : $265.77 — upside -0%
🎯 on JNJ : no call matured yet · 📊 on Health : 46.5% · +1.6% (402 calls)
in progress (365j)
matures : Jul 16, 27
matures : Jul 16, 27
RBC Capital ↗
Jul 16, 26
▲ Outperform · 🎯$287
Price at call : $253.04 — upside +13%
Today : $265.77 — upside +8%
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 16, 27
matures : Jul 16, 27
Wells Fargo ↗
Jul 16, 26
▲ Overweight · 🎯$272
Price at call : $253.04 — upside +7%
Today : $265.77 — upside +2%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jul 16, 27
matures : Jul 16, 27
Morgan Stanley ↗
Jul 16, 26
▲ Overweight · 🎯$294
Price at call : $249.97 — upside +18%
Today : $265.77 — upside +11%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 16, 27
matures : Jul 16, 27
▲ Buy · 🎯$300
Price at call : $253.85 — upside +18%
Today : $265.77 — upside +13%
🎯 on JNJ : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
See the other 69 calls, newest to oldest
RBC Capital ↗
Jul 13, 26
▲ Outperform · 🎯$287
Price at call : $253.85 — upside +13%
Today : $265.77 — upside +8%
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 13, 27
matures : Jul 13, 27
B of A Securities ↗
Jul 10, 26
■ Neutral neutral · not a buy · 🎯$263
Price at call : $257.77 — gap to target +2%
Today : $265.77 — gap to target -1%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
Morgan Stanley ↗
Jul 8, 26
▲ Overweight · 🎯$284
Price at call : $259.1 — upside +10%
Today : $265.77 — upside +7%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
▲ Buy · 🎯$298
Price at call : $259.1 — upside +15%
Today : $265.77 — upside +12%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jul 8, 27
matures : Jul 8, 27
Guggenheim ↗
Jun 26, 26
▲ Buy · 🎯$270
Price at call : $258.51 — upside +4%
Today : $265.77 — upside +2%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jun 26, 27
matures : Jun 26, 27
Leerink Partners ↗
May 13, 26
▲ Outperform · 🎯$265
Price at call : $230.8 — upside +15%
Today : $265.77 — upside -0%
🎯 on JNJ : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : May 13, 27
matures : May 13, 27
■ Equal-Weight neutral · not a buy · 🎯$255
Price at call : $234.54 — gap to target +9%
Today : $265.77 — gap to target -4%
🎯 on JNJ : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Apr 15, 27
matures : Apr 15, 27
■ Hold neutral · not a buy · 🎯$250
Price at call : $234.54 — gap to target +7%
Today : $265.77 — gap to target -6%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Apr 15, 27
matures : Apr 15, 27
Wells Fargo ↗
Apr 15, 26
▲ Overweight · 🎯$263
Price at call : $234.54 — upside +12%
Today : $265.77 — upside -1%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Apr 15, 27
matures : Apr 15, 27
Morgan Stanley ↗
Apr 10, 26
▲ Overweight · 🎯$267
Price at call : $237.96 — upside +12%
Today : $265.77 — upside +0%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Apr 10, 27
matures : Apr 10, 27
RBC Capital ↗
Mar 30, 26
▲ Outperform · 🎯$255
Price at call : $244.44 — upside +4%
Today : $265.77 — upside -4%
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Mar 30, 27
matures : Mar 30, 27
■ Equal-Weight neutral · not a buy · 🎯$234
Price at call : $235.37 — gap to target -1%
Today : $265.77 — gap to target -12%
🎯 on JNJ : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Mar 19, 27
matures : Mar 19, 27
▲ Buy · 🎯$280
Price at call : $237.28 — upside +18%
Today : $265.77 — upside +5%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Mar 17, 27
matures : Mar 17, 27
▲ Buy · 🎯$274
Price at call : $242.04 — upside +13%
Today : $265.77 — upside +3%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Mar 11, 27
matures : Mar 11, 27
■ Neutral neutral · not a buy · 🎯$250
Price at call : $240.4 — gap to target +4%
Today : $265.77 — gap to target -6%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Mar 5, 27
matures : Mar 5, 27
RBC Capital ↗
Feb 3, 26
▲ Outperform · 🎯$255
Price at call : $234.47 — upside +9%
Today : $265.77 — upside -4%
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 3, 27
matures : Feb 3, 27
Morgan Stanley ↗
Jan 28, 26
▲ Overweight · 🎯$262
Price at call : $227.72 — upside +15%
Today : $265.77 — upside -1%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jan 28, 27
matures : Jan 28, 27
Freedom Capital Markets
Jan 27, 26
■ Hold neutral · not a buy · 🎯$220
Price at call : $227.72 — gap to target -3%
Today : $265.77 — gap to target -17%
🎯 on JNJ : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
Freedom Broker
Jan 27, 26
■ Hold neutral · not a buy · 🎯$220
Price at call : $224.44 — gap to target -2%
Today : $265.77 — gap to target -17%
🎯 on JNJ : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
Guggenheim ↗
Jan 23, 26
▲ Buy · 🎯$240
Price at call : $220.14 — upside +9%
Today : $265.77 — upside -10%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jan 23, 27
matures : Jan 23, 27
▲ Buy · 🎯$250
Price at call : $220.14 — upside +14%
Today : $265.77 — upside -6%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
B of A Securities ↗
Jan 22, 26
■ Neutral neutral · not a buy · 🎯$221
Price at call : $220.14 — gap to target +0%
Today : $265.77 — gap to target -17%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
▲ Buy · 🎯$250
Price at call : $220.14 — upside +14%
Today : $265.77 — upside -6%
🎯 on JNJ : no call matured yet · 📊 on Health : 49% · +1.0% (96 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
Morgan Stanley ↗
Jan 22, 26
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $220.14 — gap to target -9%
Today : $265.77 — gap to target -25%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
Wells Fargo ↗
Jan 22, 26
▲ Overweight · 🎯$240
Price at call : $220.14 — upside +9%
Today : $265.77 — upside -10%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
Scotiabank ↗
Jan 22, 26
▲ Sector Outperform · 🎯$265
Price at call : $220.14 — upside +20%
Today : $265.77 — upside -0%
🎯 on JNJ : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
■ Hold neutral · not a buy · 🎯$220
Price at call : $218.49 — gap to target +1%
Today : $265.77 — gap to target -17%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
■ Market Perform neutral · not a buy · 🎯$208
Price at call : $209.72 — gap to target -1%
Today : $265.77 — gap to target -22%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.7% · +5.2% (64 calls)
in progress (365j)
matures : Jan 9, 27
matures : Jan 9, 27
■ Equal-Weight neutral · not a buy · 🎯$217
Price at call : $206.91 — gap to target +5%
Today : $265.77 — gap to target -18%
🎯 on JNJ : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Dec 30, 26
matures : Dec 30, 26
Goldman Sachs ↗
Dec 19, 25
▲ Buy · 🎯$240
Price at call : $207.32 — upside +16%
Today : $265.77 — upside -10%
🎯 on JNJ : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Dec 19, 26
matures : Dec 19, 26
B of A Securities ↗
Dec 15, 25
■ Neutral neutral · not a buy · 🎯$220
Price at call : $214.17 — gap to target +3%
Today : $265.77 — gap to target -17%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
Morgan Stanley ↗
Dec 12, 25
■ Equal-Weight neutral · not a buy · 🎯$197
Price at call : $214.17 — gap to target -8%
Today : $265.77 — gap to target -26%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
▲ Buy · 🎯$232
Price at call : $211.58 — upside +10%
Today : $265.77 — upside -13%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Dec 11, 26
matures : Dec 11, 26
RBC Capital ↗
Dec 11, 25
▲ Outperform · 🎯$230
Price at call : $211.58 — upside +9%
Today : $265.77 — upside -13%
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Dec 11, 26
matures : Dec 11, 26
Guggenheim ↗
Dec 5, 25
▲ Buy · 🎯$227
Price at call : $201.93 — upside +12%
Today : $265.77 — upside -15%
🎯 on JNJ : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Dec 5, 26
matures : Dec 5, 26
■ Equal-Weight neutral · not a buy · 🎯$197
Price at call : $205.42 — gap to target -4%
Today : $265.77 — gap to target -26%
🎯 on JNJ : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Dec 2, 26
matures : Dec 2, 26
Freedom Broker
Oct 22, 25
■ Hold neutral · not a buy · 🎯$190
Price at call : $192.47 — gap to target -1%
Today : $265.77 — gap to target -29%
🎯 on JNJ : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Oct 22, 26
matures : Oct 22, 26
▲ Buy · 🎯$215
Price at call : $192.12 — upside +12%
Today : $265.77 — upside -19%
🎯 on JNJ : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Oct 15, 26
matures : Oct 15, 26
■ Hold neutral · not a buy · 🎯$190
Price at call : $192.12 — gap to target -1%
Today : $265.77 — gap to target -29%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Oct 15, 26
matures : Oct 15, 26
Raymond James ↗
Oct 15, 25
▲ Outperform · 🎯$209
Price at call : $192.12 — upside +9%
Today : $265.77 — upside -21%
🎯 on JNJ : no call matured yet · 📊 on Health : 46.5% · +1.6% (402 calls)
in progress (365j)
matures : Oct 15, 26
matures : Oct 15, 26
Morgan Stanley ↗
Oct 15, 25
■ Equal-Weight neutral · not a buy · 🎯$190
Price at call : $191.17 — gap to target -1%
Today : $265.77 — gap to target -29%
🎯 on JNJ : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 15, 26
matures : Oct 15, 26
B of A Securities ↗
Oct 15, 25
■ Neutral neutral · not a buy · 🎯$204
Price at call : $191.17 — gap to target +7%
Today : $265.77 — gap to target -23%
🎯 on JNJ : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Oct 15, 26
matures : Oct 15, 26
RBC Capital ↗
Jul 17, 25
▲ Outperform · 🎯$185
Price at call : $163.7 — upside +13%
Today : $265.77 — upside -30%
Expected +13% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+52.0%
stock +52% · XLV +21%
matured Jul 17, 26
RBC Capital ↗
Jun 5, 25
▲ Outperform · 🎯$181
Price at call : $155.03 — upside +17%
Today : $265.77 — upside -32%
Expected +17% · Actual +50% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+49.8%
stock +50% · XLV +14%
matured Jun 5, 26
Leerink Partners ↗
May 13, 25
■ Market Perform neutral · not a buy · 🎯$153
Price at call : $146.36 — gap to target +5%
Today : $265.77 — gap to target -42%
🎯 on JNJ : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : May 13, 26
matures : May 13, 26
RBC Capital ↗
Apr 16, 25
▲ Outperform · 🎯$181
Price at call : $157.47 — upside +15%
Today : $265.77 — upside -32%
Expected +15% · Actual +49% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+48.7%
stock +49% · XLV +10%
matured Apr 16, 26
RBC Capital ↗
Apr 3, 25
▲ Outperform · 🎯$181
Price at call : $153.24 — upside +18%
Today : $265.77 — upside -32%
Expected +18% · Actual +57% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+57.3%
stock +57% · XLV +8%
matured Apr 3, 26
RBC Capital ↗
Apr 2, 25
▲ Outperform · 🎯$181
Price at call : $159.82 — upside +13%
Today : $265.77 — upside -32%
Expected +13% · Actual +51% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+50.8%
stock +51% · XLV +2%
matured Apr 2, 26
RBC Capital ↗
Feb 19, 25
▲ Outperform · 🎯$181
Price at call : $159.68 — upside +13%
Today : $265.77 — upside -32%
Expected +13% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+51.9%
stock +52% · XLV +7%
matured Feb 19, 26
RBC Capital ↗
Jan 23, 25
▲ Outperform · 🎯$181
Price at call : $146.82 — upside +23%
Today : $265.77 — upside -32%
Expected +23% · Actual +51% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+50.9%
stock +51% · XLV +10%
matured Jan 23, 26
Leerink Partners ↗
Jan 23, 25
▲ Outperform · 🎯$169
Price at call : $146.82 — upside +15%
Today : $265.77 — upside -36%
Expected +15% · Actual +51% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
+50.9%
stock +51% · XLV +10%
matured Jan 23, 26
Cantor Fitzgerald ↗
Oct 16, 24
▲ Overweight · 🎯$215
Price at call : $164.47 — upside +31%
Today : $265.77 — upside -19%
Expected +31% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+17.5%
stock +17% · XLV -6%
matured Oct 16, 25
RBC Capital ↗
Oct 16, 24
▲ Outperform · 🎯$181
Price at call : $164.28 — upside +10%
Today : $265.77 — upside -32%
Expected +10% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+17.0%
stock +17% · XLV -7%
matured Oct 16, 25
Cantor Fitzgerald ↗
Oct 10, 24
▲ Overweight · 🎯$215
Price at call : $161.46 — upside +33%
Today : $265.77 — upside -19%
Expected +33% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+18.2%
stock +18% · XLV -8%
matured Oct 10, 25
RBC Capital ↗
Oct 8, 24
▲ Outperform · 🎯$178
Price at call : $160.65 — upside +11%
Today : $265.77 — upside -33%
Expected +11% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+18.9%
stock +19% · XLV -6%
matured Oct 8, 25
Cantor Fitzgerald ↗
Sep 30, 24
▲ Overweight · 🎯$215
Price at call : $162.06 — upside +33%
Today : $265.77 — upside -19%
Expected +33% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+14.4%
stock +14% · XLV -10%
matured Sep 30, 25
Cantor Fitzgerald ↗
Sep 23, 24
▲ Overweight · 🎯$215
Price at call : $163.22 — upside +32%
Today : $265.77 — upside -19%
Expected +32% · Actual +8% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+8.2%
stock +8% · XLV -11%
matured Sep 23, 25
RBC Capital ↗
Sep 20, 24
▲ Outperform · 🎯$175
Price at call : $163.22 — upside +7%
Today : $265.77 — upside -34%
Expected +7% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+6.7%
stock +7% · XLV -12%
matured Sep 20, 25
Cantor Fitzgerald ↗
Sep 19, 24
▲ Overweight · 🎯$215
Price at call : $164.16 — upside +31%
Today : $265.77 — upside -19%
Expected +31% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+6.1%
stock +6% · XLV -12%
matured Sep 19, 25
Cantor Fitzgerald ↗
Sep 16, 24
▲ Overweight · 🎯$215
Price at call : $166.99 — upside +29%
Today : $265.77 — upside -19%
Expected +29% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+5.7%
stock +6% · XLV -13%
matured Sep 16, 25
Cantor Fitzgerald ↗
Sep 9, 24
▲ Overweight · 🎯$215
Price at call : $166.61 — upside +29%
Today : $265.77 — upside -19%
Expected +29% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+6.2%
stock +6% · XLV -11%
matured Sep 9, 25
Cantor Fitzgerald ↗
Sep 3, 24
▲ Overweight · 🎯$215
Price at call : $167.36 — upside +28%
Today : $265.77 — upside -19%
Expected +28% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+6.8%
stock +7% · XLV -12%
matured Sep 3, 25
Cantor Fitzgerald ↗
Aug 5, 24
▲ Overweight · 🎯$215
Price at call : $158.97 — upside +35%
Today : $265.77 — upside -19%
Expected +35% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+7.3%
stock +7% · XLV -12%
matured Aug 5, 25
Cantor Fitzgerald ↗
Jul 30, 24
▲ Overweight · 🎯$215
Price at call : $157.85 — upside +36%
Today : $265.77 — upside -19%
Expected +36% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+4.4%
stock +4% · XLV -13%
matured Jul 30, 25
RBC Capital ↗
Jul 30, 24
▲ Outperform · 🎯$175
Price at call : $161.33 — upside +8%
Today : $265.77 — upside -34%
Expected +8% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+3.7%
stock +4% · XLV -11%
matured Jul 30, 25
Daiwa Capital ↗
Jul 23, 24
■ Neutral neutral · not a buy · 🎯$150
Price at call : $152.35 — gap to target -2%
Today : $265.77 — gap to target -44%
🎯 on JNJ : no call matured yet · 📊 on Health : 40% · -1.0% (5 calls)
in progress (365j)
matures : Jul 23, 25
matures : Jul 23, 25
RBC Capital ↗
Jul 18, 24
▲ Outperform · 🎯$175
Price at call : $154.69 — upside +13%
Today : $265.77 — upside -34%
Expected +13% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
+6.3%
stock +6% · XLV -11%
matured Jul 18, 25
Cantor Fitzgerald ↗
Jul 1, 24
▲ Overweight · 🎯$215
Price at call : $146.03 — upside +47%
Today : $265.77 — upside -19%
Expected +47% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+6.5%
stock +7% · XLV -6%
matured Jul 1, 25
Cantor Fitzgerald ↗
Jun 25, 24
▲ Overweight · 🎯$215
Price at call : $146.82 — upside +46%
Today : $265.77 — upside -19%
Expected +46% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on JNJ : 100% (12 calls matureds) · 📊 on Health : 38.3% · -3.4% (342 calls)
+3.5%
stock +4% · XLV -8%
matured Jun 25, 25
Frequently asked questions
Should I buy Johnson & Johnson stock?
This isn't buy advice. For Johnson & Johnson, the analyst consensus is "Buy", with an average price target of $280 (+5% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Johnson & Johnson). We show the numbers — you decide.
Is it too late to buy Johnson & Johnson? How high can it go?
The most bullish analyst target on Johnson & Johnson is $300 (+13% above today's price); the average is $280. That's the upside they see. Check how reliable those analysts have actually been on Johnson & Johnson on our site before trusting it.
Is Johnson & Johnson still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 15 analysts have a real record on Johnson & Johnson, the best hitting 100% over 4 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Johnson & Johnson? The case for and against
The arguments for and against, one by one, from the numbers: why invest in JNJ (and why hesitate).
What has Johnson & Johnson's past performance been?
Historical returns and a "how much if I had invested" calculator: JNJ performance & returns.
Does Johnson & Johnson pay a dividend?
Yield, consistency and growth history of the dividend: JNJ's dividend.
What is the best month to buy JNJ?
The 12 months ranked by the stock's past returns: best & worst month to buy JNJ.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX